OSE Immunotherapeutics Identifies Monoclonal Antibody Antagonists of CLEC-1 as New Checkpoint Inhibitors of Immune Myeloid Cells in Immuno-Oncology

Oral and Poster Presentations at AACR Virtual Meeting II 2020 – June 22-24

• New myeloid immune checkpoint pathway identified and characterized
• Preclinical progress reported with CLEC-1 monoclonal antibody antagonists blocking the “Don’t Eat Me” signal
• Antibody antagonists targeting this new immune checkpoint represent a novel approach in cancer immunotherapy  

NANTES, France, June 09, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) announces the presentation of the identification and characterization of a new myeloid checkpoint target, CLEC-1 (a C-type lectin receptor), and of the first monoclonal antibody antagonists of CLEC-1 identified as an innovative step in cancer immunotherapy, in both an oral⁽¹⁾ and a poster presentation⁽²⁾ at the American Association of Cancer Research (AACR) Virtual Annual Meeting II, to be held on June 22-24, 2020.

Tumor cells inhibit myeloid cells phagocytosis through CLEC-1. The antagonists developed by OSE block the new CLEC-1/CLEC-1L myeloid checkpoint and constitute a novel cancer immunotherapy, in particular synergistic with chemotherapy.

Nicolas Poirier, Chief Scientific Officer of OSE Immunotherapeutics, comments: “We are very pleased to share the results of our research collaboration in the field of myeloid cells and macrophages. Our teams have characterized the myeloid checkpoint CLEC-1 as a new therapeutic target in immuno-oncology and identified monoclonal antibody antagonists blocking this novel ‘Don’t Eat Me’ signal that increase both tumor cell phagocytosis by macrophages and antigen capture by dendritic cells. The identification of CLEC-1 and its antagonists constitute an exciting innovative step in cancer immunotherapy.”

An oral presentation ⁽¹⁾ by the Company’s partner Dr. Elise Chiffoleau (Center for Research in Transplantation and Immunology, UMR - INSERM 1064, Nantes University Hospital) describes the identification of CLEC-1 as a novel myeloid immune checkpoint regulating anti-tumor responses.

OSE Immunotherapeutics’ poster presentation⁽²⁾ features its CLEC-1 antagonist monoclonal antibodies, which have been identified as an innovative immunotherapy that releases the brakes on macrophage phagocytosis and dendritic cells and demonstrates synergistic anti-cancer effects, in particular when paired with chemotherapy.

(1)

AACR Virtual Annual Meeting II oral presentation details